AEON Biopharma, Inc. (AEON) Stock Score, Valuation & Financial Research

AEON Biopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AEON

AEON Biopharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.30. These figures are a research snapshot, not a buy or sell recommendation.

What AEON Biopharma, Inc. does

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

AEON Biopharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the development and future commercialization of its lead product candidate, ABP-450, a botulinum toxin complex, for various therapeutic indications.

Products and services

  • The company's primary product candidate is ABP-450 (prabotulinumtoxinA), which is being developed as a biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic uses.

Brands and product families

  • ABP-450 — Lead product candidate being developed as a biosimilar to BOTOX. Source

Customer types

Healthcare providers and patients requiring therapeutic botulinum toxin treatments.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and future commercial supply; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Daewoong Pharmaceutical Co., Ltd. — The company has an exclusive license agreement with Daewoong for the development and distribution of ABP-450 in the U.S., Canada, the European Union, the United Kingdom, and other select international markets. Source

Competitors and product-market comparisons

  • AbbVie Inc. — Manufacturer of BOTOX, the reference product for the company's ABP-450 biosimilar program. Source

Business strengths to evaluate

  • Exclusive development and distribution rights for ABP-450 in major global markets Source
  • Management team with extensive experience in the botulinum toxin market Source

Business risks and research considerations

  • History of operating losses and dependence on additional capital to fund operations Source
  • Reliance on a single product candidate (ABP-450) and third-party manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AEON financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.30
Market capitalization:
13.25M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -54.62M
Free cash flow:
USD -17.31M
Cash:
USD 3.43M
Total debt:
USD 2.78M
EPS:
USD -3.77

What stands out

  • Free cash flow is USD -17.31M, negative for the stored period.
  • The balance sheet shows USD 3.43M of cash versus USD 2.78M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 656K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AEON

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AEON fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does AEON's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for AEON to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of AEON's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research AEON

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.